Angstrom Scientific Publications
Journal Articles
Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brünner N, Jones TR, Silverman MH, Gold MA. Gynecol Oncol 99:50-57 (2005)
Safety, Tolerability, And Pharmacokinetics Of Subcutaneous Å6, An 8-Amino Acid Peptide With Anti-Angiogenic Properties, In Healthy Men. A-R van Troostenburg, D Lee, T R Jones, J A Dyck-Jones, M H Silverman, G N Lam, S J Warrington International Journal of Clinical Pharmacology and Therapeutics 42:253-259 (May 2004)
Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6 Koh HJ, Bessho K, Cheng L, Bartsch DU, Jones TR, Bergeron-Lynn G, Freeman WR. Invest Ophthalmol Vis Sci. 45(2):635-40. (2004)
The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target McGuire PG, Jones TR, Talarico N, Warren E, Das A. Investigative Ophthalmology and Visual Science 44, 2736-2742 (2003)
A Urokinase-Derived Peptide (A6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE. American Journal of Pathology 162, 619-626, (2003)
An Antiangiogenic Urokinase-derived Peptide Combined with Tamoxifen DecreasesTumor Growth and Metastasis in a Syngeneic Model of Breast Cancer Yong Jing Guo, Andrew P. Mazar, Jean-Jacques Lebrun and Shafaat A. Rabbani Cancer Res. 62, 4678-4684 (2002)
A Three-Dimensional and Temporo-Spatial Model to Study Invasiveness of Cancer Cells by Heregulin and Prostaglandin E2 Adam, L., Mazumdar, A., Sharma, T., Jones, T. R., and Kumar, R. Cancer Res., 61, 81-87 (2001)
The Urokinase Plasminogen Activator Receptor (uPAR) is a Chokepoint for Carcinoma Metastasis and Angiogenesis. Mazar, A.P., Gawlak, S., Goldfarb, R.H., Kitson, R.P., Rabbani, S.A., Guo, Y., Gown, A., and Jones, T.R. Recent Res. Devel. Cancer, 2 , 1-12 (2000)
A Peptide Derived from the Non-receptor-binding Region of Urokinase Plasminogen Activator Inhibits Glioblastoma Growth and Angiogenesis in vivo in Combination with Cisplatin. Mishima, K., Mazar, A.P., Gown, A., Skelly, M., Ji, X.-D., Wang X.-D., Jones, T.R., Cavenee, W.K., and Su Huang, H.-J. Proc. Natl. Acad. Sci. USA, 97, 8484-8489 (2000)
A Peptide Derived from the Nonreceptor Binding Region of Urokinase Plasminogen Activator (uPA) Inhibits Tumor Progression and Angiogenesis and Induces Tumor Cell Death in vivo. Guo, Y., Higazi, A. A-R. , Arakelian, A., Sachais, B.S., Cines, D., Goldfarb, R.H., Jones, T.R., Kwaan, H., Mazar, A.P., and Rabbani, S.A. FASEB J., 14, 1400-1410 (2000)
The Urokinase Plasminogen Activator System in Cancer: Implications for tumor angiogenesis and metastasis. Mazar, A.P., Henkin, J., and Goldfarb, R.H. Angiogenesis, 3 (1) 15 (1999)
Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src. Requirement of an Upstream Motif ( 152/135) Bound with Sp1. Allgayer, H.,Wang. H., Gallick, G.E., Crabtree, A., Mazar, A., Jones,T., Kraker, A.J., and Boyd, D.D. Journal of Biological Chemistry, 274 18428 (1999).
Abstracts
The uPA/uPAR System in Choroidal Neovascularization: A Target for Anti-Angiogenic Therapy A.Das, P.G. McGuire, T.R. Jones, N.Talarico, E.Warren, Association for Research in Vision and Ophthalmology, Inc., Fort Lauderdale, Florida (2003)